Analysis of selective target engagement by small-molecule sphingosine kinase inhibitors using the Cellular Thermal Shift Assay (CETSA)

References

• Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature. 2012;483:531–533.
   PubMed Web of Science ®Google Scholar
• Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, Surber BW, Ready DB, Soni NB, Ladror US, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2012;18:510–523. doi:10.1158/1078-0432.CCR-11-1973.
   PubMed Web of Science ®Google Scholar
• Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012;18:1655–1662. doi:10.1158/1078-0432.CCR-11-2890.
   PubMed Web of Science ®Google Scholar
• Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA. 2007;104:4106–4111. doi:10.1073/pnas.0608798104.
   PubMed Web of Science ®Google Scholar
• Du J, Yan L, Torres R, Gong X, Bian H, Marugan C, Boehnke K, Baquero C, Hui Y-H, Chapman SC, et al. Aurora A selective inhibitor LY3295668 leads to dominant mitotic arrest, apoptosis in cancer cells and shows potent preclinical antitumor efficacy. Mol Cancer Ther. 2019;18:2207–2219. doi:10.1158/1535-7163.MCT-18-0529.
   PubMed Web of Science ®Google Scholar
• Gong X, Du J, Parsons SH, Merzoug FF, Webster Y, Iversen PW, Chio L-C, Van Horn RD, Lin X, Blosser W, et al. Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene. Cancer Discov. 2019;9:248–263. doi:10.1158/2159-8290.CD-18-0469.
   PubMed Web of Science ®Google Scholar
• Pulkoski-Gross MJ, Obeid LM. Molecular mechanisms of regulation of sphingosine kinase 1. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863:1413–1422. doi:10.1016/j.bbalip.2018.08.015.
   PubMed Web of Science ®Google Scholar
• Song DD, Zhou JH, Sheng R. Regulation and function of sphingosine kinase 2 in diseases. Histol Histopathol. 2018;33:433–445. doi:10.14670/HH-11-939.
   PubMed Web of Science ®Google Scholar
• Neubauer HA, Pitson SM. Roles, regulation and inhibitors of sphingosine kinase 2. Febs J. 2013;280:5317–5336. doi:10.1111/febs.12314.
   PubMed Web of Science ®Google Scholar
• Hait NC, Bellamy A, Milstien S, Kordula T, Spiegel S. Sphingosine kinase type 2 activation by ERK-mediated phosphorylation. J Biol Chem. 2007;282:12058–12065. doi:10.1074/jbc.M609559200.
   PubMedGoogle Scholar
• Neubauer HA, Pham DH, Zebol JR, Moretti PA, Peterson AL, Leclercq TM, Chan H, Powell JA, Pitman MR, Samuel MS, et al. An oncogenic role for sphingosine kinase 2. Oncotarget. 2016;7:64886–64899. doi:10.18632/oncotarget.11714.
   PubMedGoogle Scholar
• Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem. 2003;278:46832–46839. doi:10.1074/jbc.M306577200.
   PubMed Web of Science ®Google Scholar
• Ding G, Sonoda H, Yu H, Kajimoto T, Goparaju SK, Jahangeer S, Okada T, Nakamura S-I. Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2. J Biol Chem. 2007;282:27493–27502. doi:10.1074/jbc.M701641200.
   PubMed Web of Science ®Google Scholar
• Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 2009;325:1254–1257. doi:10.1126/science.1176709.
   PubMed Web of Science ®Google Scholar
• French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003;63:5962–5969.
   PubMed Web of Science ®Google Scholar
• Plano D, Amin S, Sharma AK. Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors. J Med Chem. 2014;57:5509–5524. doi:10.1021/jm4011687.
   PubMed Web of Science ®Google Scholar
• Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, Milstien S, Adams JK, Zipkin RE, Grant S, et al. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood. 2008;112:1382–1391. doi:10.1182/blood-2008-02-138958.
   PubMed Web of Science ®Google Scholar
• Wong L, Tan SS, Lam Y, Melendez AJ. Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases. J Med Chem. 2009;52:3618–3626. doi:10.1021/jm900121d.
   PubMed Web of Science ®Google Scholar
• Schnute ME, McReynolds MD, Kasten T, Yates M, Jerome G, Rains JW, Hall T, Chrencik J, Kraus M, Cronin C, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012;444:79–88. doi:10.1042/BJ20111929.
   PubMed Web of Science ®Google Scholar
• French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, Upson JJ, Green CL, Keller SN, Smith CD, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther. 2010;333:129–139. doi:10.1124/jpet.109.163444.
   PubMed Web of Science ®Google Scholar
• Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, Kellogg GE, Grant S, Spiegel S, Zhang S, et al. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PloS One. 2013;8:e56471. doi:10.1371/journal.pone.0056471.
   PubMed Web of Science ®Google Scholar
• Gustin DJ, Li Y, Brown ML, Min X, Schmitt MJ, Wanska M, Wang X, Connors R, Johnstone S, Cardozo M, et al. Structure guided design of a series of sphingosine kinase (SphK) inhibitors. Bioorg Med Chem Lett. 2013;23:4608–4616. doi:10.1016/j.bmcl.2013.06.030.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Asmussen G, Booker M, Hirth B, Kane JL Jr., Liao J, Noson KD, Yee C. Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett. 2009;19:6119–6121. doi:10.1016/j.bmcl.2009.09.022.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Hirth B, Kane JL Jr., Liao J, Noson KD, Yee C, Asmussen G, Fitzgerald M, Klaus C, Booker M, et al. Discovery of novel sphingosine kinase-1 inhibitors. Part 2. Bioorg Med Chem Lett. 2010;20:4550–4554. doi:10.1016/j.bmcl.2010.06.019.
   PubMed Web of Science ®Google Scholar
• Mathews TP, Kennedy AJ, Kharel Y, Kennedy PC, Nicoara O, Sunkara M, Morris AJ, Wamhoff BR, Lynch KR, Macdonald TL, et al. Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors. J Med Chem. 2010;53:2766–2778. doi:10.1021/jm901860h.
   PubMed Web of Science ®Google Scholar
• Raje MR, Knott K, Kharel Y, Bissel P, Lynch KR, Santos WL. Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors. Bioorg Med Chem. 2012;20:183–194. doi:10.1016/j.bmc.2011.11.011.
   PubMed Web of Science ®Google Scholar
• Patwardhan NN, Morris EA, Kharel Y, Raje MR, Gao M, Tomsig JL, Lynch KR, Santos WL. Structure−Activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors. J Med Chem. 2015;58:1879–1899. doi:10.1021/jm501760d.
   PubMed Web of Science ®Google Scholar
• Childress ES, Kharel Y, Brown AM, Bevan DR, Lynch KR, Santos WL. Transforming sphingosine kinase 1 inhibitors into dual and sphingosine kinase 2 selective inhibitors: design, synthesis, and in vivo activity. J Med Chem. 2017;60:3933–3957. doi:10.1021/acs.jmedchem.7b00233.
   PubMedGoogle Scholar
• Sharma AK, Sk UH, Gimbor MA, Hengst JA, Wang X, Yun J, Amin S. Synthesis and bioactivity of sphingosine kinase inhibitors and their novel aspirinyl conjugated analogs. Eur J Med Chem. 2010;45:4149–4156. doi:10.1016/j.ejmech.2010.06.005.
   PubMed Web of Science ®Google Scholar
• Hengst JA, Wang X, Sk UH, Sharma AK, Amin S, Yun JK. Development of a sphingosine kinase 1 specific small-molecule inhibitor. Bioorg Med Chem Lett. 2010;20:7498–7502. doi:10.1016/j.bmcl.2010.10.005.
   PubMed Web of Science ®Google Scholar
• Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundback T, Nordlund P, Molina DM. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014;9:2100–2122. doi:10.1038/nprot.2014.138.
   PubMed Web of Science ®Google Scholar
• Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, Sreekumar L, Cao Y, Nordlund P. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 2013;341:84–87. doi:10.1126/science.1233606.
   PubMed Web of Science ®Google Scholar
• Martinez Molina D, Nordlund P. The cellular thermal shift assay: a Novel biophysical assay for in situ drug target engagement and mechanistic biomarker studies. Annu Rev Pharmacol Toxicol. 2016;56:141–161. doi:10.1146/annurev-pharmtox-010715-103715.
   PubMed Web of Science ®Google Scholar
• Dick TE, Hengst JA, Fox TE, Colledge AL, Kale VP, Sung SS, Sharma A, Amin S, Loughran TP, Kester M, et al. The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines. J Pharmacol Exp Ther. 2015;352:494–508. doi:10.1124/jpet.114.219659.
   PubMed Web of Science ®Google Scholar
• Hengst JA, Dick TE, Sharma A, Doi K, Hegde S, Tan SF, Geffert L, Fox T, Sharma A, Desai D, et al. SKI-178: a multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models. Cancer Transl Med. 2017;3:109–121. doi:10.4103/ctm.ctm_7_17.
   PubMedGoogle Scholar
• Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, Milstien S, Kohama T, Spiegel S. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem. 2000;275:19513–19520. doi:10.1074/jbc.M002759200.
   PubMed Web of Science ®Google Scholar
• Gao P, Peterson YK, Smith RA, Smith CD. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PloS One. 2012;7:e44543. doi:10.1371/journal.pone.0044543.
   PubMed Web of Science ®Google Scholar
• Lim KG, Tonelli F, Li Z, Lu X, Bittman R, Pyne S, Pyne NJ. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem. 2011;286:18633–18640. doi:10.1074/jbc.M111.220756.
   PubMed Web of Science ®Google Scholar
• Olivera A, Kohama T, Tu Z, Milstien S, Spiegel S. Purification and characterization of rat kidney sphingosine kinase. J Biol Chem. 1998;273:12576–12583. doi:10.1074/jbc.273.20.12576.
   PubMed Web of Science ®Google Scholar
• Neubauer HA, Pitson SM. Validation of commercially available sphingosine kinase 2 antibodies for use in immunoblotting, immunoprecipitation and immunofluorescence. F1000Res. 2016;5:2825. doi:10.12688/f1000research.10336.1.
   PubMedGoogle Scholar
• Ju T, Gao D, Fang ZY. Targeting colorectal cancer cells by a novel sphingosine kinase 1 inhibitor PF-543. Biochem Biophys Res Commun. 2016;470:728–734. doi:10.1016/j.bbrc.2016.01.053.
   PubMed Web of Science ®Google Scholar
• Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112–1116. doi:10.1038/nprot.2006.179.
   PubMed Web of Science ®Google Scholar
• Byun HS, Pyne S, Macritchie N, Pyne NJ, Bittman R. Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells. Medchemcomm. 2013;4:1394. doi:10.1039/c3md00201b.
   Web of Science ®Google Scholar
• Tonelli F, Lim KG, Loveridge C, Long J, Pitson SM, Tigyi G, Bittman R, Pyne S, Pyne NJ. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal. 2010;22:1536–1542. doi:10.1016/j.cellsig.2010.05.022.
   PubMed Web of Science ®Google Scholar
• Loveridge C, Tonelli F, Leclercq T, Lim KG, Long JS, Berdyshev E, Tate RJ, Natarajan V, Pitson SM, Pyne NJ, et al. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J Biol Chem. 2010;285:38841–38852. doi:10.1074/jbc.M110.127993.
   PubMed Web of Science ®Google Scholar
• McNaughton M, Pitman M, Pitson SM, Pyne NJ, Pyne S. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells. Oncotarget. 2016;7:16663–16675. doi:10.18632/oncotarget.7693.
   PubMedGoogle Scholar
• Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 2003;554:189–193. doi:10.1016/S0014-5793(03)01168-2.
   PubMed Web of Science ®Google Scholar
• Lima S, Takabe K, Newton J, Saurabh K, Young MM, Leopoldino AM, Hait NC, Roberts JL, Wang H-G, Dent P, et al. TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition. Autophagy. 2018;14:942–957. doi:10.1080/15548627.2018.1429875.
   PubMed Web of Science ®Google Scholar
• Young MM, Takahashi Y, Fox TE, Yun JK, Kester M, Wang HG. Sphingosine kinase 1 cooperates with autophagy to maintain endocytic membrane trafficking. Cell Rep. 2016;17:1532–1545. doi:10.1016/j.celrep.2016.10.019.
   PubMed Web of Science ®Google Scholar
• Qin Z, Dai L, Trillo-Tinoco J, Senkal C, Wang W, Reske T, Bonstaff K, Del Valle L, Rodriguez P, Flemington E, et al. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther. 2014;13:154–164. doi:10.1158/1535-7163.MCT-13-0466.
   PubMed Web of Science ®Google Scholar
• Wallington-Beddoe CT, Powell JA, Tong D, Pitson SM, Bradstock KF, Bendall LJ. Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression. Cancer Res. 2014;74:2803–2815. doi:10.1158/0008-5472.CAN-13-2732.
   PubMed Web of Science ®Google Scholar
• Savitski MM, Reinhard FB, Franken H, Werner T, Savitski MF, Eberhard D, Molina DM, Jafari R, Dovega RB, Klaeger S, et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science. 2014;346:1255784. doi:10.1126/science.1255784.
   PubMed Web of Science ®Google Scholar
• Cingolani F, Casasampere M, Sanllehi P, Casas J, Bujons J, Fabrias G. Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II. J Lipid Res. 2014;55:1711–1720. doi:10.1194/jlr.M049759.
   PubMed Web of Science ®Google Scholar